Tuesday, November 17, 2026

HK inno.N Corp.'s K-CAB Wins Brazilian Marketing Approval, Expanding Push Into Latin America

Input
2026-11-17 09:13:41
Updated
2026-11-17 09:13:41
The K-CAB series, a new drug for gastroesophageal reflux disease. Courtesy of HK inno.N Corp.
[Financial News] K-CAB, HK inno.N Corp.'s treatment for gastroesophageal reflux disease, will enter Brazil, the largest pharmaceutical market in Latin America (LATAM). It is the first Korean-developed treatment in the potassium-competitive acid blocker (P-CAB) class to receive marketing approval in Brazil, providing a foothold for expanding into the LATAM market.
HK inno.N Corp. said on the 17th that K-CAB, its new drug for gastroesophageal reflux disease (active ingredient: tegoprazan), had received marketing approval from the Brazilian Health Regulatory Agency (ANVISA).
K-CAB will be sold under the local brand name TREV through Brazilian pharmaceutical company Eurofarma. The three approved indications are erosive gastroesophageal reflux disease, non-erosive gastroesophageal reflux disease and gastric ulcers.
Brazil is the largest pharmaceutical market in LATAM, and the local market for peptic ulcer drugs is estimated at about 1.1 trillion won as of 2025. HK inno.N Corp. plans to use this approval as a springboard to expand its local market share and strengthen its business base in LATAM.
The company has also secured a local supply chain. The active pharmaceutical ingredient for K-CAB supplied to Brazil is produced at the Daeso Plant in Chungbuk. Last year, the plant received ANVISA certification for compliance with good manufacturing practice (GMP) standards for the manufacture and quality control of tegoprazan active pharmaceutical ingredients.
In 2022, HK inno.N Corp. signed a technology transfer agreement for K-CAB with Brazilian pharmaceutical company Eurofarma, which operates in 24 countries worldwide. The two companies are preparing to launch the product following local approval.
K-CAB, launched in South Korea in 2019, was the country's 30th domestically developed new drug. Cumulative outpatient prescription sales reached 1.0433 trillion won through the first half of this year. The company has signed technology-export or finished-product export agreements covering 55 countries worldwide, including China, Southeast Asia and LATAM. K-CAB has received marketing approval in 25 of those countries and is on sale in 22.

[email protected] Jung Sang-hee Reporter